NeoGenomics, Inc. (NASDAQ:NEO) has earned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $16.80.
A number of brokerages have recently issued reports on NEO. BidaskClub cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Royal Bank of Canada set a $23.00 price objective on shares of NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. CIBC set a $19.00 price objective on shares of NeoGenomics and gave the company a “neutral” rating in a research note on Wednesday, January 3rd. Finally, Janney Montgomery Scott restated a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th.
Several institutional investors have recently made changes to their positions in NEO. Janus Henderson Group PLC acquired a new stake in shares of NeoGenomics during the 2nd quarter worth about $20,651,000. Russell Investments Group Ltd. increased its position in shares of NeoGenomics by 25.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,496,623 shares of the medical research company’s stock worth $27,786,000 after purchasing an additional 499,913 shares in the last quarter. Columbus Circle Investors acquired a new stake in shares of NeoGenomics during the 3rd quarter worth about $4,779,000. Segall Bryant & Hamill LLC grew its holdings in NeoGenomics by 318.0% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 374,068 shares of the medical research company’s stock worth $4,163,000 after acquiring an additional 284,572 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in NeoGenomics by 60.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 649,060 shares of the medical research company’s stock worth $5,816,000 after acquiring an additional 244,434 shares during the last quarter. Institutional investors and hedge funds own 83.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Brokerages Set NeoGenomics, Inc. (NEO) Price Target at $16.80” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/29/brokerages-set-neogenomics-inc-neo-price-target-at-16-80.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.